News

HuMax-TF is a fully human antibody targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. As per the deal, Genmab gets development and cGMP

Two-thirds of the enrolled patients were less than four years old. Shigamabs consists of two monoclonal antibodies which bind to the Shiga toxin 1 and Shiga toxin 2

As part of the acquisition, Biostar has changed its name to Shaanxi Weinan Aoxing Pharmaceuticals. Next to the acquisition, Biostar has increased its portfolio of drug approvals and

Rivastigmine Capsules are the generic forms of Novartis’ Exelon Capsules. Mylan chairman and CEO Robert Coury said they are excited to be adding generic Rivastigmine to their portfolio

According to the deal, Gilead will pay GlobeImmune an upfront payment and provide support for continued development of GlobeImmune’s HBV therapeutic vaccine programme through Phase 1a clinical trials.

The antibody is a dye conjugate which will be used in Phase I and Phase II clinical trials. Spectros CEO David Benaron said the collaboration with GBI on

Sativex has been developed by the UK-based GW Pharmaceuticals and is marketed in Europe (except the UK) by Almirall. The Phase III studies demonstrated the long term efficacy

Under the terms of thecollaboration, Mirna will provide Silence with specific miRNA sequences, to formulate with AtuPLEX and DBTC delivery systems and develop multiple candidate drugs. Mirna, on

Lead researcher Professor Nakajima discovered the Rheumatoid Arthritis (RA) biomarker and therapeutic target Synoviolin/Hrd1, a ubiquitin E3 ligase overexpressed in RA patients. As per the terms of the